Ivonescimab + Chemo Approved in China by NMPA for 1L Treatment of Patients with Squamous NSCLC
“The NMPA approval of ivonescimab in China in combination with chemotherapy for first-line advanced squamous NSCLC represents a landmark achievement for patients, physicians and the field of oncology. Based on the HARMONi-6 trial, ivonescimab has now demonstrated both progression-free survival and overall survival superiority versus a PD-1 inhibitor plus chemotherapy regimen, establishing a new benchmark in one of the most widely treated settings in cancer care,” said Dr. Michelle Xia, Chairwoman and Chief Executive Officer of Akeso. “This third approval for an ivonescimab-containing regimen in China reflects the strength of Akeso’s innovation platform, the dedication of our clinical investigators and patients, and the transformative potential of ivonescimab as a next-generation immuno-oncology therapy. Together with Summit, we are committed to bringing the full potential of ivonescimab to patients worldwide.”
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000